Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Vivi Li -- 1305 2022-11-08 01:41:20

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Drotrecogin Alfa. Encyclopedia. Available online: https://encyclopedia.pub/entry/33495 (accessed on 25 September 2026).
HandWiki. Drotrecogin Alfa. Encyclopedia. Available at: https://encyclopedia.pub/entry/33495. Accessed September 25, 2026.
HandWiki. "Drotrecogin Alfa" Encyclopedia, https://encyclopedia.pub/entry/33495 (accessed September 25, 2026).
HandWiki. (2022, November 08). Drotrecogin Alfa. In Encyclopedia. https://encyclopedia.pub/entry/33495
HandWiki. "Drotrecogin Alfa." Encyclopedia. Web. 08 November, 2022.
Drotrecogin Alfa
Edit
The content is sourced from: https://handwiki.org/wiki/Chemistry:Drotrecogin_alfa

Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.

drotrecogin severe sepsis anti-inflammatory

References

  1. Martí-Carvajal, Arturo J.; Solà, Ivan; Gluud, Christian; Lathyris, Dimitrios; Cardona, Andrés Felipe (2012-12-12). "Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients". The Cochrane Database of Systematic Reviews 12: CD004388. doi:10.1002/14651858.CD004388.pub6. ISSN 1469-493X. PMID 23235609.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6464614
  2. "Eli Lilly Annual Report, 2001". http://lilly.com/investor/annual_report/lillyar2001editorial.pdf. 
  3. "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly". N. Engl. J. Med. 355 (16): 1640–2. October 2006. doi:10.1056/NEJMp068197. PMID 17050887.  https://dx.doi.org/10.1056%2FNEJMp068197
  4. Barclay L (2002-10-01). "Controversy Brews Over Xigris' Role in Treating Sepsis". Medscape Medical News. WebMD LLC. http://www.medscape.com/viewarticle/442255. 
  5. Knox R (2006-10-18). "Report: Lilly Promoted Drug Under False Pretenses". All Things Considered. National Public Radio. https://www.npr.org/templates/story/story.php?storyId=6298643. 
  6. "Risks and benefits of activated protein C treatment for severe sepsis". N. Engl. J. Med. 347 (13): 1027–30. September 2002. doi:10.1056/NEJMsb020574. PMID 12324562.  https://dx.doi.org/10.1056%2FNEJMsb020574
  7. "FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated) due to failure to show a survival benefit"]. U.S. Department of Health and Human Services. October 25, 2011. https://www.fda.gov/Drugs/DrugSafety/ucm277114.htm. 
  8. Angus, Derek C.; van der Poll, Tom (29 August 2013). "Severe Sepsis and Septic Shock". New England Journal of Medicine 369 (9): 840–851. doi:10.1056/NEJMra1208623. PMID 23984731.  https://dx.doi.org/10.1056%2FNEJMra1208623
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 948
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 08 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback